Cargando…

The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

The ubiquitin-proteasome pathway is responsible for most eukaryotic intracellular protein degradation. This pathway has been validated as a target for antineoplastic therapy using both in vitro and preclinical models of human malignancies, and is influenced as part of the mechanism of action of cert...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlowski, Robert Z, Dees, E Claire
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154126/
https://www.ncbi.nlm.nih.gov/pubmed/12559038
http://dx.doi.org/10.1186/bcr460
_version_ 1782120738893856768
author Orlowski, Robert Z
Dees, E Claire
author_facet Orlowski, Robert Z
Dees, E Claire
author_sort Orlowski, Robert Z
collection PubMed
description The ubiquitin-proteasome pathway is responsible for most eukaryotic intracellular protein degradation. This pathway has been validated as a target for antineoplastic therapy using both in vitro and preclinical models of human malignancies, and is influenced as part of the mechanism of action of certain chemotherapeutic agents. Drugs whose primary action involves modulation of ubiquitin-proteasome activity, most notably the proteasome inhibitor PS-341, are currently being evaluated in clinical trials, and have already been found to have significant antitumor efficacy. On the basis of the known mechanisms by which these agents work, and the available clinical data, they would seem to be well suited for the treatment of breast neoplasms. Such drugs, alone and especially in combination with current chemotherapeutics, may well represent important advances in the therapy of patients with breast cancer.
format Text
id pubmed-154126
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1541262003-05-06 The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer Orlowski, Robert Z Dees, E Claire Breast Cancer Res Review The ubiquitin-proteasome pathway is responsible for most eukaryotic intracellular protein degradation. This pathway has been validated as a target for antineoplastic therapy using both in vitro and preclinical models of human malignancies, and is influenced as part of the mechanism of action of certain chemotherapeutic agents. Drugs whose primary action involves modulation of ubiquitin-proteasome activity, most notably the proteasome inhibitor PS-341, are currently being evaluated in clinical trials, and have already been found to have significant antitumor efficacy. On the basis of the known mechanisms by which these agents work, and the available clinical data, they would seem to be well suited for the treatment of breast neoplasms. Such drugs, alone and especially in combination with current chemotherapeutics, may well represent important advances in the therapy of patients with breast cancer. BioMed Central 2003 2002-08-14 /pmc/articles/PMC154126/ /pubmed/12559038 http://dx.doi.org/10.1186/bcr460 Text en Copyright © 2003 BioMed Central Ltd
spellingShingle Review
Orlowski, Robert Z
Dees, E Claire
The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
title The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
title_full The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
title_fullStr The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
title_full_unstemmed The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
title_short The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
title_sort role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154126/
https://www.ncbi.nlm.nih.gov/pubmed/12559038
http://dx.doi.org/10.1186/bcr460
work_keys_str_mv AT orlowskirobertz theroleoftheubiquitinationproteasomepathwayinbreastcancerapplyingdrugsthataffecttheubiquitinproteasomepathwaytothetherapyofbreastcancer
AT deeseclaire theroleoftheubiquitinationproteasomepathwayinbreastcancerapplyingdrugsthataffecttheubiquitinproteasomepathwaytothetherapyofbreastcancer
AT orlowskirobertz roleoftheubiquitinationproteasomepathwayinbreastcancerapplyingdrugsthataffecttheubiquitinproteasomepathwaytothetherapyofbreastcancer
AT deeseclaire roleoftheubiquitinationproteasomepathwayinbreastcancerapplyingdrugsthataffecttheubiquitinproteasomepathwaytothetherapyofbreastcancer